ストックスクリーナーアプリを入手
0.4521
3.81%
-0.0179
Naya Biosciences (NAYA) 最新ニュース
NAYA Biosciences Raises $9.5M Amid Nasdaq Compliance Issues - TipRanks
NAYA Biosciences sets public offering at $0.70 per unit By Investing.com - Investing.com South Africa
Lakewood Ranch life sciences firm seeks to raise $9.5M through public offering - Business Observer
NAYA Stock Hits 52-Week Low at $0.62 Amid Market Challenges - Investing.com
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering - GlobeNewswire
NAYA Biosciences sets public offering at $0.70 per unit - Investing.com
NAYA Biosciences Raises $9.5M in Public Offering to Fund Acquisition and Growth Plans - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NAYA Biosciences expands oncology pipeline with new antibody By Investing.com - Investing.com Nigeria
NAYA Biosciences expands oncology pipeline with new antibody - Investing.com
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody - GlobeNewswire
NAYA Biosciences Unveils NY-500, AI-Enhanced Cancer Antibody Outperforming Keytruda - StockTitan
NAYA (NAYA Biosciences) Long-Term Debt & Capital Lease Obli - GuruFocus.com
The horror of Saydnaya jail, symbol of Assad excesses - News- Graphic
INVO Bioscience : Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System - Marketscreener.com
Grapevine December 15, 2024: Changing of the guard - The Jerusalem Post
NAYA Biosciences Inc. (NAYA) reports earnings - Quartz
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC - Marketscreener.com
INVO Bioscience changes name, trading symbol after merger - Business Observer
INVO Bioscience confirms name change, new trading symbol following NAYA merger - TipRanks
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences - The Manila Times
CERo Therapeutics, Inc. Provides Corporate Update - The Manila Times
INVO Bioscience (NASDAQ: INVO) Stock Sees Bullish Momentum on Merger News - DRP Journal
INVO Bioscience Completes Merger with NAYA Biosciences - TipRanks
Sarasota fertility company completes merger with bioscience firm - Business Observer
INVO Bioscience merges with NAYA, eyes oncology market - Investing.com
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA) - The Manila Times
Sify Technologies announces the appointment of Ms. Padmaja Chunduru as Director on the Board - The Manila Times
INVO Bioscience, NAYA Biosciences close merger - TipRanks
INVO Bioscience secures $265,000 through Merchant Cash Advance - Investing.com India
INVO Bioscience faces Nasdaq delisting over share price - Investing.com
INVO Bioscience extends merger agreement with NAYA - Investing.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Sudden doctor departure at Middleton fertility clinic leaves patients unsettled - Madison.com
Naya Biosciences - The Pharma Letter
'We wasted a year': Abrupt shakeup at Wisconsin fertility clinic leaves families scrambling for answers - Milwaukee Journal Sentinel
INVO Bioscience receives Nasdaq compliance extension - Investing.com
Trading the Gap to Win in the Pre-Market - DataDrivenInvestor
Why Is Invo Bioscience (INVO) Stock Up 85% Today? - InvestorPlace
INVO Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
INVO Bioscience Seeks Funds After NAYA Misses Deadline - TipRanks
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) - Yahoo Finance
CGT Landscape: Recent Approvals, Deals And 2024 Catalysts - In Vivo
INVO Bioscience Files S-4 Registration and Preliminary - GlobeNewswire
Ten NK cell therapy companies to look out for this year - Labiotech.eu
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered - Labiotech.eu
0.92%
0.25%
大文字化:
|
ボリューム (24 時間):